Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosemary Foster

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Oncotarget|April 1, 2015
Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancerYan Gao, Rosemary Foster, Xiaoqian Yang, et al.
Cell Cycle (Georgetown, Tex.)|February 8, 2008
Functional analyses of the cancer stem cell-like properties of human endometrial tumor initiating cellsAnne M Friel, Petra A Sergent, Christine Patnaude, et al.
Gynecologic Oncology|March 27, 2014
Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft modelJolijn W Groeneweg, Tracilyn R Hall, Ling Zhang, et al.
Gynecologic Oncology|January 21, 2015
HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variantWhitfield B Growdon, Jolijn Groeneweg, Virginia Byron, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2006
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsivenessPaul P Szotek, Rafael Pieretti-Vanmarcke, Peter T Masiakos, et al.
Gynecologic Oncology|February 25, 2014
Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancerLeslie S Bradford, Alejandro Rauh-Hain, Rachel M Clark, et al.
Science Signaling|January 19, 2017
Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated TregsHeather Torrey, John Butterworth, Toshiyuki Mera, et al.
Molecular Cancer Therapeutics|May 2, 2006
Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathwayDeborah Chirnomas, Toshiyasu Taniguchi, Michelle de la Vega, et al.
Gynecologic Oncology|December 21, 2010
Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic originWhitfield B Growdon, Breton N Roussel, Vanessa L Scialabba, et al.
Reproductive Biology and Endocrinology : RB&E|December 3, 2010
Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cellsAnne M Friel, Ling Zhang, Michael D Curley, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Oncotarget|April 1, 2015
Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancerYan Gao, Rosemary Foster, Xiaoqian Yang, et al.
Cell Cycle (Georgetown, Tex.)|February 8, 2008
Functional analyses of the cancer stem cell-like properties of human endometrial tumor initiating cellsAnne M Friel, Petra A Sergent, Christine Patnaude, et al.
Gynecologic Oncology|March 27, 2014
Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft modelJolijn W Groeneweg, Tracilyn R Hall, Ling Zhang, et al.
Gynecologic Oncology|January 21, 2015
HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variantWhitfield B Growdon, Jolijn Groeneweg, Virginia Byron, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 20, 2006
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsivenessPaul P Szotek, Rafael Pieretti-Vanmarcke, Peter T Masiakos, et al.
Gynecologic Oncology|February 25, 2014
Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancerLeslie S Bradford, Alejandro Rauh-Hain, Rachel M Clark, et al.
Science Signaling|January 19, 2017
Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated TregsHeather Torrey, John Butterworth, Toshiyuki Mera, et al.
Molecular Cancer Therapeutics|May 2, 2006
Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathwayDeborah Chirnomas, Toshiyasu Taniguchi, Michelle de la Vega, et al.
Gynecologic Oncology|December 21, 2010
Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic originWhitfield B Growdon, Breton N Roussel, Vanessa L Scialabba, et al.
Reproductive Biology and Endocrinology : RB&E|December 3, 2010
Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cellsAnne M Friel, Ling Zhang, Michael D Curley, et al.
Pageof 4